Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio)immunotherapy of renal cell carcinoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 4, 2003, Pages 539-547

  Brouwers, Adrienne H ^a   Frielink, Cathelijne ^a   Oosterwijk, Egbert ^a   Oyen, Wim J G ^a   Corstens, Frans H M ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Immunotherapy; Interferons; Monoclonal antibodies; Radioimmunotherapy; Renal cell cancer

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; EPITOPE; G250 MN CA IX ANTIGEN; GAMMA INTERFERON; IMMUKINE; INTERFERON; MONOCLONAL ANTIBODY; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SCATCHARD PLOT;

EID: 0041836180     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803322287619     Document Type: Article

References (36)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7.
2. Ritchie AW, Chisholm GD. The natural history of renal carcinoma. Semin Oncol 1983;10:390.
3. Sandock DS, Seftel AD, Resnick MI. A new protocol for the followup of renal cell carcinoma based on pathological stage. J Urol 1995;154:28.
4. Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z. Patterns of failure following surgical resection of renal cell carcinoma: Implications for adjuvant local and systemic therapy. J Clin Oncol 1994;12:206.
5. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995;22:42.
6. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998;338:1272.
7. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6[suppl. 1]:S55.
8. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997;15:1529.
9. 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 1999;5(suppl 10):3268s.
10. Pastorek J, Pastorekova S, Callebaut I, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 1994;9:2877.
11. Kaluz S, Kaluzova M, Opavsky R, et al. Transcriptional regulation of the MN/CA 9 gene coding for the tumor-associated carbonic anhydrase IX: Identification and characterization of a proximal silencer element. J Biol Chem 1999;274:32588.
12. Grabmaier K, Vissers JL, De Weijert MC, et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 2000;85: 865.
13. Uemura H, Nakagawa Y, Yoshida K, et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 1999;81:741.
14. Scher HI, Motzer RJ, Bladder and renal cell cancer. Harrison's principles of internal medicine, 14th ed. Fauci AS, Braunwald E, Isselbacher KJ et al. eds. The McGraw-Hill Companies, New York. 1998;1:592.
15. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 1986;38:489.
16. Pastorekova S, Parkkila S, Parkkila AK, et al. Carbonic anhydrase IX, MN/CA IX: Analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1997;112: 398.
17. Beasley NJ, Wykoff CC, Watson PH, et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 2001;61:5262.
18. McKieman JM, Buttyan R, Bander NH, et al. Expression of the tumor-associated gene MN: A potential biomarker for human renal cell carcinoma. Cancer Res 1997;57:2362.
19. Greiner JW, Guadagni F, Noguchi P, et al. Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science 1987;235:895.
20. Pfeffer LM, Dinarello CA, Herberman RB, et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998;58:2489.
21. Tran R, Hand PH, Greiner JW, et al. Enhancement of surface antigen expression on human breast carcinoma cells by recombinant human interferons. J Interferon Res 1988;8:75.
22. Shimada S, Ogawa M, Schlom J, Greiner JW. Comparison of the interferon-gamma-mediated regulation of tumor-associated antigens expressed by human gastric carcinoma cells. In Vivo 1993;7:1.
23. Mobus VJ, Asphal W, Knapstein PG, Kreienberg R. Effects of interferon gamma on the proliferation and modulation of cell-surface structures of human ovarian carcinoma cell lines. J Cancer Res Clin Oncol 1993; 120:27.
24. Guadagni F, Witt PL, Robbins PF, Schlom J, et al. Regulation of carcinoembryonic antigen expression in different human colorectal tumor cells by interferon-gamma. Cancer Res 1990;50:6248.
25. Dansky Ullmann C, Salgaller M, Adams S, et al. Synergistic effects of IL-6 and IFN-gamma on carcinoembryonic antigen (CEA) and HLA expression by human colorectal carcinoma cells: Role for endogenous IFN-beta. Cytokine 1995;7:118.
26. 131I-CC49) when given in combination with gamma-interferon. Cancer Res 1993;53:600.
27. 131I-labeled monoclonal antibody CC49 in breast cancer: A phase II trial. Clin Cancer Res 1997;3:1547.
28. Roselli M, Guadagni F, Buonomo O, et al. Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinoma-associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen. J Clin Oncol 1996;14:2031.
29. Kranenborg MH, Boerman OC, De Weijert MC, et al. The effect of antibody protein dose of anti-renal cell carcinoma monoclonal antibodies in nude mice with renal cell carcinoma xenografts. Cancer 1997;80:2390.
30. Ebert T, Bander NH, Finstad CL, et al. Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res 1990;50:5531.
31. Scatchard G. The attractions of proteins for small molecules and ions. Ann NY Acad Sci 1949;51:660.
32. Greiner JW, Hand PH, Noguchi P, et al. Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment. Cancer Res 1984;44:3208.
33. Margolin KA. Interleukin-2 in the treatment of renal cancer. Semin Oncol 2000;27:194.
34. Verhaar Langereis MJ, Bongers V, De Klerk JM, et al. Interferon-alpha induced changes in CEA expression in patients with CEA-producing tumours. Eur J Nucl Med 2000;27:209.
35. Van Dijk J, Uemura H, Beniers AJ, et al. Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts. Int J Cancer 1994;56:262.
36. Beniers AJ, Van Moorselaar RJ, Peelen WP, et al. Differential sensitivity of renal cell carcinoma xenografts towards therapy with interferon-alpha, interferon-gamma, tumor necrosis factor and their combinations. Urol Res 1991;19:91.